文献速递消化道肿瘤与早癌消化内镜

基于粪便免疫化学检测的优先排序以减轻COVID-19大流行期间结直肠癌2周等待转诊路径延迟的影响:英国建模研究

Prioritisation by FIT to mitigate the impact of delays in the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling study.
PubMed 文献 · Gut · 2020-08-27

该英国建模研究评估了COVID-19大流行期间结直肠癌2周等待(2WW)路径延迟对生存的影响,并模拟了以粪便免疫化学检测(FIT)阈值2、10和150 µg Hb/g进行优先排序的缓解策略。结果显示,2WW路径延迟2/4/6个月可导致653/1419/2250例归因死亡和9214/20315/32799寿命年损失;对FIT>10 µg Hb/g的症状性转诊者优先排序可避免89%的归因死亡,同时减少>80%的即时结肠镜检查需求。

要点

  • 2WW路径延迟2/4/6个月估计导致653/1419/2250例归因死亡和9214/20315/32799寿命年损失。
  • 对FIT>10 µg Hb/g的18%症状性转诊者优先排序可避免89%的归因死亡,减少>80%即时结肠镜检查需求。
  • FIT在症状性患者中假阴性率可观,大多数结肠镜检查仍需要。

核心结论

  • 2WW路径延迟可能造成显著死亡和寿命年损失。
  • FIT对初级保健中症状性患者的分诊可简化结肠镜获取、减少真阳性CRC病例的延迟并降低老年真阴性2WW转诊者的院内COVID-19死亡。
  • 该策略仅在短期合理分配有限内镜服务时带来获益:症状性患者中FIT的假阴性率可观,意味着大多数结肠镜检查仍将需要。

研究设计与样本

  • 建模研究,模拟2WW路径中每例患者延迟2-6个月导致的CRC生存下降和寿命年损失。
  • 按年龄组分层,比较CRC生存获益与每例转诊接受结肠镜检查者年龄特异性院内COVID-19相关病死率。
  • 使用FIT分诊阈值2、10和150 µg Hb/g模拟优先排序2WW转诊进行结肠镜的缓解策略。
  • 基础模型采用英格兰2008-2017年10年净CRC生存、2WW路径CRC病例和转诊量以及来自诊断至治疗间隔观察性研究的每延迟一天HR。

主要发现

  • 在典型年份通过2WW路径诊断的所有11266例CRC患者中,延迟2/4/6个月估计导致653/1419/2250例归因死亡和9214/20315/32799寿命年损失。
  • 对于年龄>60岁的患者,紧急检查转诊的风险-获益对院内COVID-19发生率特别敏感。
  • 对FIT>10 µg Hb/g的18%症状性转诊者优先排序可避免89%的归因于就诊/诊断延迟的死亡,同时减少>80%的即时结肠镜检查需求。

临床怎么用

  • 作者认为,初级保健中对症状性患者进行FIT分诊可简化结肠镜获取、减少真阳性CRC病例的延迟并降低老年真阴性2WW转诊者的院内COVID-19死亡。
  • 作者指出,该策略仅在短期合理分配有限内镜服务时带来获益:症状性患者中FIT的假阴性率可观,意味着大多数结肠镜检查仍将需要。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the impact of faecal immunochemical testing (FIT) prioritisation to mitigate the impact of delays in the colorectal cancer (CRC) urgent diagnostic (2-week-wait (2WW)) pathway consequent from the COVID-19 pandemic. DESIGN: We modelled the reduction in CRC survival and life years lost resultant from per-patient delays of 2-6 months in the 2WW pathway. We stratified by age group, individual-level benefit in CRC survival versus age-specific nosocomial COVID-19-related fatality per referred patient undergoing colonoscopy. We modelled mitigation strategies using thresholds of FIT triage of 2, 10 and 150 µg Hb/g to prioritise 2WW referrals for colonoscopy. To construct the underlying models, we employed 10-year net CRC survival for England 2008-2017, 2WW pathway CRC case and referral volumes and per-day-delay HRs generated from observational studies of diagnosis-to-treatment interval. RESULTS: Delay of 2/4/6 months across all 11 266 patients with CRC diagnosed per typical year via the 2WW pathway were estimated to result in 653/1419/2250 attributable deaths and loss of 9214/20 315/32 799 life years. Risk-benefit from urgent investigatory referral is particularly sensitive to nosocomial COVID-19 rates for patients aged >60. Prioritisation out of delay for the 18% of symptomatic referrals with FIT >10 µg Hb/g would avoid 89% of these deaths attributable to presentational/diagnostic delay while reducing immediate requirement for colonoscopy by >80%. CONCLUSIONS: Delays in the pathway to CRC diagnosis and treatment have potential to cause significant mortality and loss of life years. FIT triage of symptomatic patients in primary care could streamline access to colonoscopy, reduce delays for true-positive CRC cases and reduce nosocomial COVID-19 mortality in older true-negative 2WW referrals. However, this strategy offers benefit only in short-term rationalisation of limited endoscopy services: the appreciable false-negative rate of FIT in symptomatic patients means most colonoscopies will still be required.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Loveday C, Sud A, Jones ME, et al. Prioritisation by FIT to mitigate the impact of delays in the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling study. Gut. 2020. PMID: 32855306. doi:10.1136/gutjnl-2020-321650

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。